Ariad Unfazed By FDA Breakthrough Denial
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA denied a “breakthrough” designation request for ALK/EGFR inhibitor AP26113, but the door is open for another try, and the undaunted company is launching a pivotal trial in NSCLC this quarter. Ariad also reported a continued successful launch of its leukemia drug Iclusig.
You may also be interested in...
Ariad’s Leukemia Drug Iclusig Sails Through FDA In Less Than 3 Months
Ponatinib received accelerated approval for use in chronic myeloid leukemia and acute lymphoblastic leukemia patients who are resistant or intolerant to prior therapy with tyrosine kinase inhibitors.
New Drugs Build On Personalized Medicine Momentum In Lung Cancer
Crop of new treatments with data at the European Society of Medical Oncology meeting includes second-generation inhibitors of ALK and heat shock protein 90.
Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.